ATAI Life Sciences NV
NASDAQ:ATAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Total Bangun Persada Tbk PT
IDX:TOTL
|
ID |
ATAI Life Sciences NV
Research & Development
ATAI Life Sciences NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Research & Development
-$51.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Research & Development
-€5.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Merck KGaA
XETRA:MRK
|
Research & Development
-€2.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ATAI Life Sciences NV
Glance View
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
See Also
What is ATAI Life Sciences NV's Research & Development?
Research & Development
-51.6m
USD
Based on the financial report for Dec 31, 2025, ATAI Life Sciences NV's Research & Development amounts to -51.6m USD.
What is ATAI Life Sciences NV's Research & Development growth rate?
Research & Development CAGR 5Y
-35%
Over the last year, the Research & Development growth was 5%. The average annual Research & Development growth rates for ATAI Life Sciences NV have been 11% over the past three years , -35% over the past five years .
